Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6784 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-12

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

NCT01800006

Atrial Fibrillation

COMPLETED

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

NCT02960880

Atrial Fibrillation

COMPLETED

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

NCT02864758

Atrial Fibrillation

COMPLETED

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647

Atrial Fibrillation

COMPLETED PHASE3

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540

Nonvalvular Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Multiple Locations, , Austria

Site Status

Multiple Locations, , Belgium

Site Status

Multiple Locations, , Canada

Site Status

Multiple Locations, , Czechia

Site Status

Multiple Locations, , Denmark

Site Status

Multiple Locations, , France

Site Status

Multiple Locations, , Germany

Site Status

Multiple Locations, , Hungary

Site Status

Multiple Locations, , Ireland

Site Status

Multiple Locations, , Israel

Site Status

Multiple Locations, , Moldova

Site Status

Multiple Locations, , Netherlands

Site Status

Multiple Locations, , Norway

Site Status

Multiple Locations, , Poland

Site Status

Multiple Locations, , Portugal

Site Status

Multiple Locations, , Russia

Site Status

Multiple Locations, , Slovakia

Site Status

Multiple Locations, , Slovenia

Site Status

Multiple Locations, , Sweden

Site Status

Multiple Locations, , Ukraine

Site Status

Multiple Locations, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Canada Czechia Denmark France Germany Hungary Ireland Israel Moldova Netherlands Norway Poland Portugal Russia Slovakia Slovenia Sweden Ukraine United Kingdom